In a filing, Regenxbio Inc revealed its President and CEO Mills Kenneth T. unloaded Company’s shares for reported $0.33 million on Mar 14 ’24. In the deal valued at $21.86 per share,15,000 shares were sold. As a result of this transaction, Mills Kenneth T. now holds 408,035 shares worth roughly $7.38 million.
Then, PAKOLA STEVE sold 12,878 shares, generating $365,220 in total proceeds. Upon selling the shares at $28.36, the Chief Medical Officer now owns 107,192 shares.
Before that, Mills Kenneth T. sold 15,000 shares. Regenxbio Inc shares valued at $251,349 were divested by the President and CEO at a price of $16.76 per share. As a result of the transaction, Mills Kenneth T. now holds 408,035 shares, worth roughly $7.38 million.
H.C. Wainwright initiated its Regenxbio Inc [RGNX] rating to a Buy in a research note published on March 11, 2024; the price target was $36. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who increased its forecast for the stock in early March from “a Sector perform” to “an Outperform”. Leerink Partners also remained covering RGNX and has increased its forecast on March 06, 2024 with a “an Outperform” recommendation from previously “Market perform” rating.
Price Performance Review of RGNX
On Friday, Regenxbio Inc [NASDAQ:RGNX] saw its stock fall -4.89% to $18.09. Over the last five days, the stock has lost -5.63%. Regenxbio Inc shares have risen nearly 0.78% since the year began. Nevertheless, the stocks have risen 2.09% over the past one year. While a 52-week high of $28.80 was reached on 03/05/24, a 52-week low of $11.83 was recorded on 02/02/24. SMA at 50 days reached $19.48, while 200 days put it at $17.96. A total of 0.54 million shares were traded, compared to the trading of 0.36 million shares in the previous session.
Levels Of Support And Resistance For RGNX Stock
The 24-hour chart illustrates a support level at 17.35, which if violated will result in even more drops to 16.62. On the upside, there is a resistance level at 19.10. A further resistance level may holdings at 20.12. The Relative Strength Index (RSI) on the 14-day chart is 35.03, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.42, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.40%. Stochastics %K at 14.18% indicates the stock is a buying.
The most recent change occurred on November 01, 2023 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $35 price target.
